Business UpdateMay 4, 2026, 04:32 PM
BioAge Labs to Host R&D Day for BGE-102 Phase 1 Clinical Data
AI Summary
BioAge Labs announced it will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for its lead product candidate, BGE-102. The event will focus on the NLRP3 inflammasome inhibitor's therapeutic rationale for atherosclerotic cardiovascular disease (ASCVD) and retinal disease. BioAge management will be joined by four leading experts to discuss NLRP3 biology and the diseases BGE-102 aims to treat. The company anticipates Phase 2 cardiovascular risk data in H2 2026 and Phase 1b/2a diabetic macular edema data in mid-2027.
Key Highlights
- BioAge Labs to host R&D Day webcast on May 8, 2026, from 12:30 to 2 PM ET.
- Event will feature Phase 1 clinical data for BGE-102, an NLRP3 inflammasome inhibitor.
- Therapeutic rationale for BGE-102 in ASCVD and retinal disease will be discussed.
- Four academic and clinical experts will join BioAge management for presentations.
- BGE-102 completed Phase 1 SAD/MAD trial, showing well-tolerated profile.
- Phase 2 cardiovascular risk data anticipated in H2 2026.
- Phase 1b/2a diabetic macular edema data anticipated in mid-2027.
Price Impact
More from BIOA